Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:00 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Minimize Menorrhagia in Women With Von Willebrand Disease
NCT02606045 · Margaret Ragni · PHASE3 · terminated · last registry update 2024-07-01 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study stopped early due to slow recruitment.” | – | Registry record, Margaret Ragni |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against VWF within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-05-31Phase 3 first posted: Hoffmann-La Roche, Emicizumab + von Willebrand Factor (VWF) Concentrates (NCT06998524)
- 2024-12-04Phase 3 first posted: Swedish Orphan Biovitrum, Efanesoctocog alfa (NCT06716814)
- 2024-11-26Results posted on the registry: Washington University School of Medicine, Transdermal patch + Daily Sublingual Tablet (NCT05010707)
- 2024-02-13Results posted on the registry: Bioverativ, a Sanofi company, efanesoctocog alfa (BIVV001) (NCT04759131)
- 2024-01-12Phase 3 first posted: Unity Health Toronto, Lyophilized concentrate of human coagulation von Willebrand Factor and factor VIII (NCT06205095)
- 2023-10-25Results posted on the registry: Octapharma, Wilate (NCT04052698)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision